Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MCRB
Strong SellSinkerSeres Therapeutics, Inc. · Healthcare · United States · $51M · Avg Vol: $313K/d
8
StockRankGet insider-trade alerts
Q
38
V
33
M
9
P/E (TTM)
—
ROE
-66.6%
D/E
1.6x
Dividend %
—
COMPANY DESCRIPTION
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0.8M | — | 1.9M | 13.8M | 0.3M | -41.1% |
| EPS | -46.20 | -17.77 | 0.00 | 0.64 | — | -2.48 | -3.52 | -4.95 | — |
| Shares | 6.3M | 6.8M | 8.7M | 9.6M | +52.6% | 10.0M | — | — | — |
| Debt | 162.6M | 198.8M | 91.6M | 83.0M | -20.1% | 56.6M | — | — | — |
| Equity | 10.8M | -44.9M | 13.8M | 44.2M | 60.1% | — | — | — | — |
| Op CF | -228.8M | -117.4M | -148.6M | 1.1M | — | -51.3M | — | — | — |
| Inv CF | 82.4M | 10.6M | 142.3M | -42.0K | — | — | — | — | — |
| Fin CF | 129.6M | 71.7M | -90.4M | 13.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+6.7%
SMA 50SMA 200
Close
$5.10
RSI (14)
59.9
52W High
$29.98
From 52W High
0.2%
SCORE BREAKDOWN
Quality
38
ROIC
18.0%88.4
ROE
-66.6%14.6
GP/Assets
-33.3%2.6
Op. Margin
-2101.4%5.3
FCF/Assets
n/mN/A
Piotroski
677.4
Int. Cover
50.0x89.2
D/E Ratio
1.64x7.2
Current Ratio
2.11x40.8
Value
33
P/E (TTM)
—N/A
EV/EBITDA
-1.2x25.0
P/FCF
n/mN/A
P/B
1.5x74.2
P/S
27.3x13.1
Div Yield
—N/A
Momentum
9
52W High %
17%2.6
RS 6M
-56%10.6
SMA 50/200
0.56x3.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-99%5.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$51M
P/E (Forward)
-1.0x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MCRB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MCRB | Seres Therapeutics, Inc.(you) | $51M | 8 | Strong Sell |
| TCRX | TScan Therapeutics, Inc. | $51M | 7 | Strong Sell |
| TIL | Instil Bio, Inc. | $51M | 9 | Strong Sell |
| ATYR | aTyr Pharma, Inc. | $53M | 7 | Strong Sell |
| CNTX | Context Therapeutics Inc. | $56M | 6 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| ELOX | Eloxx Pharmaceuticals, Inc. | $52M | 15 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| HYPD | Hyperion DeFi, Inc. | $51M | 16 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%